Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03381196




Registration number
NCT03381196
Ethics application status
Date submitted
18/12/2017
Date registered
21/12/2017
Date last updated
24/05/2021

Titles & IDs
Public title
A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing Complications
Scientific title
A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection Who Are at Risk of Developing Complications
Secondary ID [1] 0 0
2017-002217-59
Secondary ID [2] 0 0
CR108400
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Influenza A 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Pimodivir 600 mg
Treatment: Drugs - Placebo
Other interventions - SOC Treatment

Experimental: Treatment Arm 1 (pimodivir + SOC treatment) - Participants will receive pimodivir 600 milligram (mg), orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with Standard-of-Care (SOC) treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected adverse event (AE).

Placebo comparator: Treatment Arm 2 (placebo + SOC treatment) - Participants will receive placebo matching to pimodivir orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6) along with SOC treatment. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon). An influenza antiviral as part of the SOC cannot be changed (for example, switching one influenza antiviral for another) during the treatment period, with the exception that an influenza antiviral may be discontinued in the case of a suspected AE.


Treatment: Drugs: Pimodivir 600 mg
Participants will receive pimodivir 600 mg, orally, twice daily, for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of pimodivir on Day 1 \[evening\], dosing will continue until the morning of Day 6).

Treatment: Drugs: Placebo
Participants will receive placebo matching to pimodivir, orally twice daily for 5 days (on Days 1 through 5; for participants who will receive only 1 dose of placebo on Day 1 \[evening\], dosing will continue until the morning of Day 6).

Other interventions: SOC Treatment
Participants may receive SOC treatment as a part of background therapy. The SOC treatment is determined by the investigator based on local practice, and may include influenza antivirals and/or supportive care only. The choice to use influenza antivirals as part of the SOC should be made before randomization. The influenza antiviral should be started no later than Day 2 morning (up to noon).
Intervention code [1] 0 0
Treatment: Drugs
Intervention code [2] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Time to Resolution of 7 Primary Influenza-related Symptoms as Assessed by the Patient-Reported Outcome (PRO) Measure Flu-Intensity and Impact Questionnaire (Flu-iiQ)
Timepoint [1] 0 0
Up to Day 28
Secondary outcome [1] 0 0
Number of Participants Hospitalized After Treatment Initiation
Timepoint [1] 0 0
Up to Day 28
Secondary outcome [2] 0 0
Viral Load Over Time
Timepoint [2] 0 0
Baseline, Day 3, 6, 10, 14
Secondary outcome [3] 0 0
Number of Participants With Emergence of Viral Resistance to Pimodivir
Timepoint [3] 0 0
Up to Day 28
Secondary outcome [4] 0 0
Plasma Concentration of Pimodivir
Timepoint [4] 0 0
Day 3, 6, 7
Secondary outcome [5] 0 0
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
Timepoint [5] 0 0
Up to Day 28
Secondary outcome [6] 0 0
Number of Participants With Clinically Significant Changes in Laboratory Tests
Timepoint [6] 0 0
Up to Day 28
Secondary outcome [7] 0 0
Number of Participants With Clinically Significant Changes in Electrocardiogram (ECG)
Timepoint [7] 0 0
Up to Day 28
Secondary outcome [8] 0 0
Number of Participants With Clinically Significant Changes in Vital Signs
Timepoint [8] 0 0
Up to Day 28

Eligibility
Key inclusion criteria
* Present to the clinic with symptoms suggestive of a diagnosis of acute influenza and have at least 1 respiratory symptom and at least 1 systemic symptom, both scored as at least "moderate" if the symptom did not pre-exist before influenza onset, or scored worse than usual if the symptom pre-existed as determined by subject's ratings on Module 1 of the Flu-iiQ and the Pre-existing Symptom Questionnaire in the ePRO device. Symptoms must include the following by category: a) Respiratory symptoms: cough, sore throat, nasal congestion b) Systemic symptoms: headache, body aches or pain, feverishness, fatigue
* Tested positive for influenza A infection after the onset of symptoms, using a rapid influenza diagnostic test (RIDT) or, if available, a polymerase chain reaction (PCR)-based or other rapid molecular diagnostic assay
* Not be in need of hospitalized medical care at screening. Emergency room or hospital observation status for an anticipated duration of less than (<)24 hours is not considered hospitalization as long as a determination of the need for hospitalization has not been made
* Enrollment and initiation of study drug treatment less than or equal to (<=)72 hours after onset of influenza symptoms
* Participants 13 to 65 years of age, inclusive must also have at least 1 of the following: a) Cardiovascular or cerebrovascular disease (including congenital heart disease, chronic heart failure, coronary artery disease, or stroke; excluding isolated hypertension); b) Chronic lung disease (for example, asthma, chronic obstructive lung disease [COPD] or cystic fibrosis); c) Weakened immune system due to disease or medication (for example, participants with human immunodeficiency virus [HIV], cancer, or chronic liver or kidney disease [presence of kidney damage for >3 months, defined by structural or functional abnormalities of the kidney, with or without decreased GFR manifested by: pathological abnormalities; OR markers of kidney damage, including abnormalities in the composition of the blood or urine or abnormalities in imaging tests], or participants taking chronic systemic steroids)
Minimum age
13 Years
Maximum age
85 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Received more than (>)1 dose of influenza antiviral medication (for example, oseltamivir [OST] or zanamivir), or any dose of ribavirin within 2 weeks, prior to first study drug intake, or received intravenous (IV) peramivir >1 day prior to screening
* Unstable angina pectoris or myocardial infarction within 30 days prior to screening (inclusive)
* Presence of clinically significant heart arrhythmias, uncontrolled, unstable atrial arrhythmia, or sustained ventricular arrhythmia, or risk factors for Torsade de Pointes syndrome
* Known severe hepatic impairment (Child Pugh C cirrhosis) or chronic hepatitis C infection undergoing hepatitis C antiviral therapy
* Severely immunocompromised in the opinion of the investigator (for example, known cluster of differentiation 4 plus [CD4+] count <200 cells per cubic millimeter [cells/mm^3], absolute neutrophil count <750/mm^3, first course of chemotherapy completed within 2 weeks prior to screening, history of stem cell transplant within 1 year prior to screening, history of a lung transplant)

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Stopped early
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
21/01/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
24/08/2020
Sample size
Target
Accrual to date
Final
553
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Northside Health - Coffs Harbour
Recruitment hospital [2] 0 0
Mater Hospital Brisbane - South Brisbane
Recruitment postcode(s) [1] 0 0
2450 - Coffs Harbour
Recruitment postcode(s) [2] 0 0
4101 - South Brisbane
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Kentucky
Country [12] 0 0
United States of America
State/province [12] 0 0
Louisiana
Country [13] 0 0
United States of America
State/province [13] 0 0
Maryland
Country [14] 0 0
United States of America
State/province [14] 0 0
Massachusetts
Country [15] 0 0
United States of America
State/province [15] 0 0
Michigan
Country [16] 0 0
United States of America
State/province [16] 0 0
Missouri
Country [17] 0 0
United States of America
State/province [17] 0 0
Montana
Country [18] 0 0
United States of America
State/province [18] 0 0
Nebraska
Country [19] 0 0
United States of America
State/province [19] 0 0
Nevada
Country [20] 0 0
United States of America
State/province [20] 0 0
New Jersey
Country [21] 0 0
United States of America
State/province [21] 0 0
North Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Ohio
Country [23] 0 0
United States of America
State/province [23] 0 0
Pennsylvania
Country [24] 0 0
United States of America
State/province [24] 0 0
Rhode Island
Country [25] 0 0
United States of America
State/province [25] 0 0
South Carolina
Country [26] 0 0
United States of America
State/province [26] 0 0
South Dakota
Country [27] 0 0
United States of America
State/province [27] 0 0
Tennessee
Country [28] 0 0
United States of America
State/province [28] 0 0
Texas
Country [29] 0 0
United States of America
State/province [29] 0 0
Utah
Country [30] 0 0
United States of America
State/province [30] 0 0
Virginia
Country [31] 0 0
Argentina
State/province [31] 0 0
Bahia Blanca
Country [32] 0 0
Argentina
State/province [32] 0 0
Ciudad de Buenos Aires
Country [33] 0 0
Argentina
State/province [33] 0 0
Cordoba
Country [34] 0 0
Argentina
State/province [34] 0 0
Córdoba
Country [35] 0 0
Argentina
State/province [35] 0 0
General Roca
Country [36] 0 0
Argentina
State/province [36] 0 0
Ituzaingo
Country [37] 0 0
Argentina
State/province [37] 0 0
La Plata Lpl Lpl
Country [38] 0 0
Argentina
State/province [38] 0 0
La Plata
Country [39] 0 0
Argentina
State/province [39] 0 0
Rosario
Country [40] 0 0
Argentina
State/province [40] 0 0
Santa Fe
Country [41] 0 0
Austria
State/province [41] 0 0
Wien
Country [42] 0 0
Belgium
State/province [42] 0 0
Brussel
Country [43] 0 0
Belgium
State/province [43] 0 0
Bruxelles
Country [44] 0 0
Belgium
State/province [44] 0 0
Gozée
Country [45] 0 0
Belgium
State/province [45] 0 0
Ham
Country [46] 0 0
Belgium
State/province [46] 0 0
Herbeumont
Country [47] 0 0
Belgium
State/province [47] 0 0
Linkebeek
Country [48] 0 0
Belgium
State/province [48] 0 0
Massemen
Country [49] 0 0
Belgium
State/province [49] 0 0
Tessenderlo
Country [50] 0 0
Brazil
State/province [50] 0 0
Belo Horizonte
Country [51] 0 0
Brazil
State/province [51] 0 0
Brasil
Country [52] 0 0
Brazil
State/province [52] 0 0
Canoas
Country [53] 0 0
Brazil
State/province [53] 0 0
Jaú
Country [54] 0 0
Brazil
State/province [54] 0 0
Juiz de Fora
Country [55] 0 0
Brazil
State/province [55] 0 0
Passo Fundo
Country [56] 0 0
Brazil
State/province [56] 0 0
Porto Alegre
Country [57] 0 0
Brazil
State/province [57] 0 0
Rio de Janeiro
Country [58] 0 0
Brazil
State/province [58] 0 0
Santo André
Country [59] 0 0
Brazil
State/province [59] 0 0
São Bernardo do Campo
Country [60] 0 0
Brazil
State/province [60] 0 0
São Paulo
Country [61] 0 0
Bulgaria
State/province [61] 0 0
Ruse
Country [62] 0 0
Bulgaria
State/province [62] 0 0
Sofia
Country [63] 0 0
Bulgaria
State/province [63] 0 0
Veliko Tarnovo
Country [64] 0 0
Bulgaria
State/province [64] 0 0
Vidin
Country [65] 0 0
Canada
State/province [65] 0 0
Alberta
Country [66] 0 0
Canada
State/province [66] 0 0
Ontario
Country [67] 0 0
Canada
State/province [67] 0 0
Mount Pearl
Country [68] 0 0
Canada
State/province [68] 0 0
Quebec
Country [69] 0 0
Chile
State/province [69] 0 0
San Bernardo
Country [70] 0 0
Chile
State/province [70] 0 0
Talca
Country [71] 0 0
Chile
State/province [71] 0 0
Viña
Country [72] 0 0
China
State/province [72] 0 0
Beijing
Country [73] 0 0
China
State/province [73] 0 0
Fuzhou
Country [74] 0 0
China
State/province [74] 0 0
NanChang
Country [75] 0 0
China
State/province [75] 0 0
Wuxi
Country [76] 0 0
China
State/province [76] 0 0
Zhengzhou
Country [77] 0 0
Czechia
State/province [77] 0 0
Ceske Budejovice
Country [78] 0 0
Czechia
State/province [78] 0 0
Ceské Budejovice
Country [79] 0 0
Czechia
State/province [79] 0 0
Kyjov
Country [80] 0 0
Czechia
State/province [80] 0 0
Pribram
Country [81] 0 0
Czechia
State/province [81] 0 0
Slany
Country [82] 0 0
Czechia
State/province [82] 0 0
Sokolov
Country [83] 0 0
Estonia
State/province [83] 0 0
Paide
Country [84] 0 0
Estonia
State/province [84] 0 0
Tallinn
Country [85] 0 0
Estonia
State/province [85] 0 0
Tartu
Country [86] 0 0
France
State/province [86] 0 0
Agen cedex 9
Country [87] 0 0
France
State/province [87] 0 0
Creteil cedex
Country [88] 0 0
France
State/province [88] 0 0
La Roche S/ Yon Cedex 9
Country [89] 0 0
France
State/province [89] 0 0
La Tronche
Country [90] 0 0
France
State/province [90] 0 0
Nantes Cedex 1
Country [91] 0 0
France
State/province [91] 0 0
Nice Cedex 3
Country [92] 0 0
France
State/province [92] 0 0
Paris 75
Country [93] 0 0
France
State/province [93] 0 0
Paris
Country [94] 0 0
Germany
State/province [94] 0 0
Cottbus
Country [95] 0 0
Germany
State/province [95] 0 0
Deggingen
Country [96] 0 0
Germany
State/province [96] 0 0
Erlangen
Country [97] 0 0
Germany
State/province [97] 0 0
Giessen
Country [98] 0 0
Germany
State/province [98] 0 0
Koeln
Country [99] 0 0
Germany
State/province [99] 0 0
Kuenzing
Country [100] 0 0
Germany
State/province [100] 0 0
Leipzig
Country [101] 0 0
Hungary
State/province [101] 0 0
Balatonfured
Country [102] 0 0
Hungary
State/province [102] 0 0
Budapest
Country [103] 0 0
Hungary
State/province [103] 0 0
Gyongyos
Country [104] 0 0
Hungary
State/province [104] 0 0
Miskolc
Country [105] 0 0
Hungary
State/province [105] 0 0
Mohacs
Country [106] 0 0
Hungary
State/province [106] 0 0
Nyiregyhaza
Country [107] 0 0
Hungary
State/province [107] 0 0
Szentendre
Country [108] 0 0
Hungary
State/province [108] 0 0
Torokbalint
Country [109] 0 0
Hungary
State/province [109] 0 0
Zamardi
Country [110] 0 0
Hungary
State/province [110] 0 0
Zirc
Country [111] 0 0
India
State/province [111] 0 0
Balaga
Country [112] 0 0
India
State/province [112] 0 0
Bangalore
Country [113] 0 0
India
State/province [113] 0 0
Jaipur
Country [114] 0 0
India
State/province [114] 0 0
Lucknow
Country [115] 0 0
India
State/province [115] 0 0
Manipal
Country [116] 0 0
India
State/province [116] 0 0
Nagpur
Country [117] 0 0
India
State/province [117] 0 0
Nashik
Country [118] 0 0
India
State/province [118] 0 0
New Delhi
Country [119] 0 0
India
State/province [119] 0 0
Pune
Country [120] 0 0
India
State/province [120] 0 0
Rajkot
Country [121] 0 0
India
State/province [121] 0 0
Surat
Country [122] 0 0
Israel
State/province [122] 0 0
Ashkelon
Country [123] 0 0
Israel
State/province [123] 0 0
Haifa
Country [124] 0 0
Israel
State/province [124] 0 0
Nahariya
Country [125] 0 0
Israel
State/province [125] 0 0
Ramat Gan
Country [126] 0 0
Israel
State/province [126] 0 0
Rechovot
Country [127] 0 0
Israel
State/province [127] 0 0
Safed
Country [128] 0 0
Italy
State/province [128] 0 0
Milano
Country [129] 0 0
Italy
State/province [129] 0 0
Modena
Country [130] 0 0
Italy
State/province [130] 0 0
Monza
Country [131] 0 0
Italy
State/province [131] 0 0
Verona
Country [132] 0 0
Korea, Republic of
State/province [132] 0 0
Ansan-si
Country [133] 0 0
Korea, Republic of
State/province [133] 0 0
Cheongju-si
Country [134] 0 0
Korea, Republic of
State/province [134] 0 0
Gangwon-do
Country [135] 0 0
Korea, Republic of
State/province [135] 0 0
Hwaseong-si
Country [136] 0 0
Korea, Republic of
State/province [136] 0 0
Incheon
Country [137] 0 0
Korea, Republic of
State/province [137] 0 0
Pusan
Country [138] 0 0
Korea, Republic of
State/province [138] 0 0
Seoul
Country [139] 0 0
Korea, Republic of
State/province [139] 0 0
Suwon-si
Country [140] 0 0
Latvia
State/province [140] 0 0
Balvi
Country [141] 0 0
Latvia
State/province [141] 0 0
Daugavpils
Country [142] 0 0
Latvia
State/province [142] 0 0
Jelgava
Country [143] 0 0
Latvia
State/province [143] 0 0
Kuldiga
Country [144] 0 0
Latvia
State/province [144] 0 0
Liepaja
Country [145] 0 0
Latvia
State/province [145] 0 0
Ogre
Country [146] 0 0
Latvia
State/province [146] 0 0
Riga
Country [147] 0 0
Latvia
State/province [147] 0 0
Tukums
Country [148] 0 0
Latvia
State/province [148] 0 0
Ventspils
Country [149] 0 0
Lithuania
State/province [149] 0 0
Kaunas
Country [150] 0 0
Lithuania
State/province [150] 0 0
Siauliai
Country [151] 0 0
Lithuania
State/province [151] 0 0
Vilnius
Country [152] 0 0
Malaysia
State/province [152] 0 0
Cheras Baru
Country [153] 0 0
Malaysia
State/province [153] 0 0
Kuang
Country [154] 0 0
Malaysia
State/province [154] 0 0
Miri
Country [155] 0 0
Malaysia
State/province [155] 0 0
Taiping
Country [156] 0 0
Mexico
State/province [156] 0 0
Aguascalientes
Country [157] 0 0
Mexico
State/province [157] 0 0
Ciudad De Mexico
Country [158] 0 0
Mexico
State/province [158] 0 0
Culiacan
Country [159] 0 0
Mexico
State/province [159] 0 0
Guadalajara
Country [160] 0 0
Mexico
State/province [160] 0 0
Jojutla De Juárez
Country [161] 0 0
Mexico
State/province [161] 0 0
Monterrey
Country [162] 0 0
Mexico
State/province [162] 0 0
Pahucha
Country [163] 0 0
Netherlands
State/province [163] 0 0
Den Haag
Country [164] 0 0
Netherlands
State/province [164] 0 0
Rotterdam
Country [165] 0 0
Netherlands
State/province [165] 0 0
Zwijndrecht
Country [166] 0 0
New Zealand
State/province [166] 0 0
Auckland
Country [167] 0 0
New Zealand
State/province [167] 0 0
Papamoa
Country [168] 0 0
New Zealand
State/province [168] 0 0
Rotorua
Country [169] 0 0
New Zealand
State/province [169] 0 0
Wellington
Country [170] 0 0
Peru
State/province [170] 0 0
Lima
Country [171] 0 0
Peru
State/province [171] 0 0
Trujillo
Country [172] 0 0
Poland
State/province [172] 0 0
Krakow
Country [173] 0 0
Poland
State/province [173] 0 0
Lancut
Country [174] 0 0
Poland
State/province [174] 0 0
Lodz
Country [175] 0 0
Poland
State/province [175] 0 0
Specjalistyczna W Brzegu Dolnym
Country [176] 0 0
Poland
State/province [176] 0 0
Sucha Beskidzka
Country [177] 0 0
Poland
State/province [177] 0 0
Wroclaw
Country [178] 0 0
Russian Federation
State/province [178] 0 0
Kazan
Country [179] 0 0
Russian Federation
State/province [179] 0 0
Omsk
Country [180] 0 0
Russian Federation
State/province [180] 0 0
Saint-Petersburg
Country [181] 0 0
Russian Federation
State/province [181] 0 0
St. Petersburg
Country [182] 0 0
Russian Federation
State/province [182] 0 0
Stavropol
Country [183] 0 0
Russian Federation
State/province [183] 0 0
Tomsk
Country [184] 0 0
Russian Federation
State/province [184] 0 0
Yaroslavl
Country [185] 0 0
Slovakia
State/province [185] 0 0
Kosice
Country [186] 0 0
Slovakia
State/province [186] 0 0
Michalovce
Country [187] 0 0
Slovakia
State/province [187] 0 0
Spisska Nova Ves
Country [188] 0 0
Slovakia
State/province [188] 0 0
Svidnik
Country [189] 0 0
South Africa
State/province [189] 0 0
Alberton
Country [190] 0 0
South Africa
State/province [190] 0 0
Bloemfontein
Country [191] 0 0
South Africa
State/province [191] 0 0
Brandfort
Country [192] 0 0
South Africa
State/province [192] 0 0
Breyten
Country [193] 0 0
South Africa
State/province [193] 0 0
Cape Town
Country [194] 0 0
South Africa
State/province [194] 0 0
Chatsworth
Country [195] 0 0
South Africa
State/province [195] 0 0
Durban North
Country [196] 0 0
South Africa
State/province [196] 0 0
Durban
Country [197] 0 0
South Africa
State/province [197] 0 0
Johannesburg
Country [198] 0 0
South Africa
State/province [198] 0 0
Kempton Park
Country [199] 0 0
South Africa
State/province [199] 0 0
Krugersdorp
Country [200] 0 0
South Africa
State/province [200] 0 0
KwaZulu-Natal
Country [201] 0 0
South Africa
State/province [201] 0 0
Midrand
Country [202] 0 0
South Africa
State/province [202] 0 0
Moloto
Country [203] 0 0
South Africa
State/province [203] 0 0
Newtown
Country [204] 0 0
South Africa
State/province [204] 0 0
Ottawa
Country [205] 0 0
South Africa
State/province [205] 0 0
Port Elizabeth
Country [206] 0 0
South Africa
State/province [206] 0 0
Pretoria
Country [207] 0 0
South Africa
State/province [207] 0 0
Soweto
Country [208] 0 0
South Africa
State/province [208] 0 0
Thabazimbi
Country [209] 0 0
South Africa
State/province [209] 0 0
Van Der Bijl
Country [210] 0 0
South Africa
State/province [210] 0 0
Welkom
Country [211] 0 0
Spain
State/province [211] 0 0
Elche
Country [212] 0 0
Spain
State/province [212] 0 0
Granada
Country [213] 0 0
Spain
State/province [213] 0 0
Madrid
Country [214] 0 0
Spain
State/province [214] 0 0
Santiago de Compostela
Country [215] 0 0
Spain
State/province [215] 0 0
Vigo
Country [216] 0 0
Sweden
State/province [216] 0 0
Malmö
Country [217] 0 0
Sweden
State/province [217] 0 0
Stockholm
Country [218] 0 0
Sweden
State/province [218] 0 0
Umeå
Country [219] 0 0
Sweden
State/province [219] 0 0
Uppsala
Country [220] 0 0
Taiwan
State/province [220] 0 0
New Taipei City
Country [221] 0 0
Taiwan
State/province [221] 0 0
Taichung
Country [222] 0 0
Taiwan
State/province [222] 0 0
Taipei City
Country [223] 0 0
Taiwan
State/province [223] 0 0
Taipei
Country [224] 0 0
Thailand
State/province [224] 0 0
Bangkok
Country [225] 0 0
Thailand
State/province [225] 0 0
Muang
Country [226] 0 0
Thailand
State/province [226] 0 0
Nonthaburi
Country [227] 0 0
Thailand
State/province [227] 0 0
Wattana
Country [228] 0 0
Turkey
State/province [228] 0 0
Ankara
Country [229] 0 0
Turkey
State/province [229] 0 0
Aydin
Country [230] 0 0
Turkey
State/province [230] 0 0
Bursa
Country [231] 0 0
Turkey
State/province [231] 0 0
Diyarbakir
Country [232] 0 0
Turkey
State/province [232] 0 0
Kocaeli
Country [233] 0 0
Turkey
State/province [233] 0 0
Samanpazari, Altindag
Country [234] 0 0
Turkey
State/province [234] 0 0
Trabzon
Country [235] 0 0
Ukraine
State/province [235] 0 0
Kharkiv
Country [236] 0 0
Ukraine
State/province [236] 0 0
Kyiv
Country [237] 0 0
Ukraine
State/province [237] 0 0
Odesa
Country [238] 0 0
Ukraine
State/province [238] 0 0
Poltava
Country [239] 0 0
Ukraine
State/province [239] 0 0
Vinnytsia
Country [240] 0 0
United Kingdom
State/province [240] 0 0
Bolton
Country [241] 0 0
United Kingdom
State/province [241] 0 0
Manchester
Country [242] 0 0
United Kingdom
State/province [242] 0 0
Northenden
Country [243] 0 0
Vietnam
State/province [243] 0 0
Hanoi
Country [244] 0 0
Vietnam
State/province [244] 0 0
Ho Chi Minh

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Janssen Research & Development, LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the clinical and virologic benefit of pimodivir in combination with Standard-of-Care (SOC) treatment compared to placebo in combination with SOC treatment.
Trial website
https://clinicaltrials.gov/study/NCT03381196
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Janssen Research & Development, LLC Clinical Trial
Address 0 0
Janssen Research & Development, LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03381196